Recombinant interleukin-2 corrects in vitro the immunological defect of endometriosis

Am J Reprod Immunol. 1993 Dec;30(4):218-27. doi: 10.1111/j.1600-0897.1993.tb00623.x.

Abstract

Problem: It has been shown recently that women with endometriosis have several immunological defects. In particular, these patients have a defect in peripheral blood natural killer cell activity and have lost their capacity of recognizing and lysing autologous endometrial cells.

Method: We evaluated the effect of recombinant interleukin-2 (rIL-2) on peripheral blood lymphocytes obtained from both healthy donors and endometriosis patients. The generation of a strong cytolytic activity against autologous endometrial cells was obtained from both normal donors and endometriosis patients.

Results: Interestingly, these cytolytic cells belong to the T-cell lineage and do not recognize both autologous keratinocytes and allogeneic endometrial cells, thus suggesting a mechanism of specific recognition of autologous cells.

Conclusion: The capability of restoring cytolytic activity using rIL-2 suggests a new immunotherapeutic approach for the treatment of severe endometriosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Differentiation, T-Lymphocyte / metabolism
  • Autoimmunity
  • CD4-Positive T-Lymphocytes / immunology
  • CD8 Antigens / metabolism
  • Cells, Cultured
  • Cytotoxicity, Immunologic
  • Endometriosis / immunology*
  • Endometriosis / pathology
  • Endometriosis / therapy*
  • Female
  • Humans
  • In Vitro Techniques
  • Interleukin-2 / therapeutic use*
  • Isoantigens
  • Keratinocytes / immunology
  • Killer Cells, Natural / immunology
  • Lymphocyte Activation
  • Phenotype
  • Recombinant Proteins / therapeutic use
  • T-Lymphocyte Subsets / immunology
  • Tumor Cells, Cultured / immunology

Substances

  • Antigens, Differentiation, T-Lymphocyte
  • CD8 Antigens
  • Interleukin-2
  • Isoantigens
  • Recombinant Proteins